US Asset Management LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

US Asset Management LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$250K	Hold	504	–	–	0.19%	103
2026 Q1	$225K	Buy	504 +1	+0.2%	+$466	0.2%	111
2025 Q4	$228K	Buy	+503	New	+$217K	0.19%	109
2025 Q3	–	Sell	-507	Closed	-$226K	–	123
2025 Q2	$226K	Hold	507	–	–	0.2%	115
2025 Q1	$246K	Hold	507	–	–	0.23%	109
2024 Q4	$204K	Hold	507	–	–	0.18%	119
2024 Q3	$251K	Hold	507	–	–	0.22%	103
2024 Q2	$238K	Sell	507 -26	-5%	-$11.3K	0.21%	116
2024 Q1	$223K	Sell	533 -4	-0.7%	-$1.69K	0.2%	123
2023 Q4	$218K	Buy	+537	New	+$198K	0.22%	120
2023 Q2	–	Sell	-542	Closed	-$171K	–	226
2023 Q1	$171K	Hold	542	–	–	0.17%	128
2022 Q4	$157K	Buy	+542	New	+$165K	0.17%	139
2022 Q2	$153K	Hold	542	–	–	0.17%	138
2022 Q1	$141K	Buy	+542	New	+$129K	0.13%	146
2021 Q4	–	Sell	-542	Closed	-$98K	–	231
2021 Q3	$98K	Buy	+542	New	+$106K	0.1%	160

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

US Asset Management LLC's VRTX Position: Q2 2026 in Review

US Asset Management LLC held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 504 shares worth $250K. The position accounts for 0.19% of the portfolio, ranked #103.

US Asset Management LLC first reported a position in VRTX in Q3 2021 and has held it in 15 quarters since. The position peaked at $251K in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

US Asset Management LLC held 504 shares of Vertex Pharmaceuticals worth $250K as of Q2 2026.
US Asset Management LLC left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.19% of US Asset Management LLC's portfolio in Q2 2026, its #103 holding.
US Asset Management LLC first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
US Asset Management LLC's Vertex Pharmaceuticals position peaked at $251K in Q3 2024.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on US Asset Management LLC's 13F filing for Q2 2026, filed 12 Aug 2026.